Read the full story behind our collaboration with AWS: tinyurl.com/Latent-xAWS

The AWS partnership has been providing scalable compute through Amazon SageMaker HyperPod and an incredible community that's accelerated our mission.

Instead of waiting weeks or months for lab experiments, researchers can now get to precision breakthrough molecules at the push of a button.

Our Latent-X model uses AI to design proteins and model molecular interactions – moving beyond what nature gives us to precisely engineering what we need for therapeutics, food tech, and climate solutions.

Latent-X is available with a free tier on our platform now: platform.latentlabs.com

🔬 Mini-binders represent a new therapeutic modality — for targeted delivery, diagnostics, and therapeutic inhibitors.

For partnerships: partnerships@latentlabs.com

🚀 Available now on the Latent Labs Platform with free tier access:

* No-code interface
* Upload targets, select epitopes, generate binders
* 10x faster than previous methods
* Computational ranking for lab prioritization

🧪 Lab-validated target specificity across all tested mini-binders.

See the all-against-all binding screen via our in-house mDisplay assay below:

⚡ Watch Latent-X generate a picomolar mini-binders from scratch — solving the geometric puzzle of binding at the all-atom level in real-time.

Every atom placed with precision to create the biochemistry required for tight, specific binding.

🔬 Look at the generated non-covalent bonds — hydrogen bonds, pi-stacking, van der Waals interactions.

Latent-X doesn't just predict binding; it generates the exact biochemical interactions needed for high affinity and specificity.

🎯 Extensive lab validation shows leading performance:

* 100% target success rate (5/5 therapeutically relevant proteins)
* Picomolar binding affinities achieved
* 10-64% experimental hit rates
* Testing just ~100 designs per target vs millions traditionally

In extensive wet lab experiments, Latent-X achieved what would typically require millions of candidates by testing as little as 30-100 candidates per target—yet achieved strong binding affinities down to the picomolar ranges.

Sign-up for early access at: platform.latentlabs.com

Starting with macrocycles and mini-binders, expanding to nanobodies and more. Our mission: make biology programmable to make drug design instantaneous.
Join early access: platform.latentlabs.com
Technical report: tinyurl.com/latent-X
Technical details: www.latentlabs.com/latent-x

Latent-X solves the geometric puzzle of binding at the all-atom level, generating novel binders from scratch while obeying nature's biochemical rules.
Scientists can now access lab-validated AI workflows without needing AI expertise or infrastructure.

Traditional drug discovery screens millions of random molecules with <1% hit rates. Latent-X flips this: we generate 30-100 precise designs per target and achieve lab success rates up to 100%.

The efficiency gains are dramatic.

Learn more about the panel and the event here: uspharma.live.ft.com/agenda/sessi...

Read more about how we’re working with AWS to put AI directly into the hands of biologists, pharma, and biotech innovators around the world: shorturl.at/0t63L